Rhythm Pharmaceuticals (RYTM) net assets (shareholders' equity)

Net assets · fiscal 2025
$270.03M

Rhythm Pharmaceuticals (RYTM) had net assets of $270.03M at the end of fiscal 2025 (December 31, 2025). That is 64.1% higher than the $164.55M of fiscal 2024. Figures as of 19 Nov 2026, 11:29 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Net assets, fiscal 2025
$270.03M
Change on fiscal 2024
+64.1%
Growth, 5 years
+10.1% a year
Highest on record
$284.15Mfiscal 2021
Lowest on record
-$32.70Mfiscal 2016
Fiscal years on record
112015–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Rhythm Pharmaceuticals net assets (shareholders' equity), in more detail

Over the five fiscal years to 2025 net assets grew at a compound 10.1% a year. Across the 11 fiscal years on record (2015–2025), the highest was $284.15M in fiscal 2021 and the lowest -$32.70M in fiscal 2016.

History · 11 fiscal years

Net assets by fiscal year

Rhythm Pharmaceuticals net assets (shareholders' equity), year by year

Rhythm Pharmaceuticals (RYTM) net assets (shareholders' equity) by fiscal year
Fiscal yearNet assetsChangeYear ended
2025$270.03M 64.1% up
2024$164.55M 3.1% down
2023$169.76M 35.8% down
2022$264.26M 7.0% down
2021$284.15M 70.6% up
2020$166.53M 40.7% down
2019$281.02M 14.1% up
2018$246.26M 70.1% up
2017$144.79M—
2016-$32.70M—
2015-$8.00M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.

How to read it

Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.

Net assets at health care companies of similar size

Net assets of Rhythm Pharmaceuticals and comparable companies
CompanyNet assetsFiscal year
Rhythm Pharmaceuticals RYTM$270.03M2025
Alkermes ALKS$1.82B2025
PACS Group PACS$946.77M2025
Kiniksa Pharmaceuticals International KNSA$567.61M2025
ImmunityBio IBRX-$500.47M2025
Cytokinetics CYTK-$659.63M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on RYTM

Rhythm Pharmaceuticals, figure by figure

Rhythm Pharmaceuticals (RYTM) overview: price, valuation and scorecardAll health care companies by market value

Rhythm Pharmaceuticals net assets (shareholders' equity): questions and answers

What are Rhythm Pharmaceuticals's net assets?

Rhythm Pharmaceuticals (RYTM) had net assets of $270.03M at the end of fiscal 2025 (December 31, 2025). That is 64.1% higher than the $164.55M of fiscal 2024.

What is the growth rate of Rhythm Pharmaceuticals's net assets?

Over the five fiscal years to 2025 net assets grew at a compound 10.1% a year.

What are the highest and lowest net assets figures on record for Rhythm Pharmaceuticals?

Across the 11 fiscal years on record (2015–2025), the highest was $284.15M in fiscal 2021 and the lowest -$32.70M in fiscal 2016.

How is Rhythm Pharmaceuticals's net assets calculated?

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For Rhythm Pharmaceuticals it is on record here for 11 fiscal years, 2015 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Rhythm Pharmaceuticals (RYTM) net assets (shareholders' equity)”, data as of 19 November 2026. https://funkfolio.com/stock/RYTM/net-assets

Underlying data: the company's filings with the SEC and Yahoo Finance.